SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN

SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 265,384 shares of the company’s stock, valued at approximately $5,191,000. SG Americas Securities LLC owned about 0.19% of Dyne Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Darwin Wealth Management LLC boosted its position in Dyne Therapeutics by 0.5% during the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after buying an additional 861 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares during the last quarter. Creative Planning boosted its holdings in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the last quarter. Finally, Caxton Associates LLP increased its stake in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares during the period. 96.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Chardan Capital reissued a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Oppenheimer upgraded shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Finally, Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a research note on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Brian S. Posner bought 3,000 shares of Dyne Therapeutics stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the acquisition, the director owned 11,500 shares of the company’s stock, valued at approximately $173,190. The trade was a 35.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 14.14% of the company’s stock.

Dyne Therapeutics Stock Down 0.2%

Shares of NASDAQ DYN opened at $18.10 on Thursday. The firm has a fifty day simple moving average of $17.12 and a two-hundred day simple moving average of $17.71. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $25.00. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.99 billion, a PE ratio of -5.11 and a beta of 1.28.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.